**Tables:**

**Table 1. Statistical analysis of patient characteristics in the study and control groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **STUDY GROUP (n=70)** | **CONTROL GROUP (n=50)** | **TEST** | **p** |
| **Age**  **Mean**  **Min. – max.**  **Median**  **SD** | **50 years**  **26 – 85 years**  **49 years**  **±10,80 years** | **53.61 years**  **45-70 years**  **52 years**  **±6.47 years** | **Cochran and Cox =**  **-1.22547** | **>0,05** |
| **BMI**  **Mean**  **Min. – max.**  **Median**  **SD** | **26,83 kg/m2**  **16,02 – 41,16**  **kg/m2**  **26,57 kg/m2**  **±5,54 kg/m2** | **27,51 kg/m2**  **20,55 – 40,04 kg/m2**  **26,25 kg/m2**  **±4,56 kg/m2** | **U M-W = -0,590871** | **>0,05** |
| **Menopausal status**  **Menstruating**  **Post-menopausal** | **49 (70%)**  **21 (30%)** | **30 (60%)**  **20 (40%)** | **Chi2 Pearsona =**  **1,296697** | **>0,05** |
| **Parity**  **nulliparas**  **primiparas**  **multiparas** | **10 (14,29%)**  **20 (28,57%)**  **40 (57,14%)** | **4 (8%)**  **16 (32%)**  **30 (60%)** | **Chi2 Pearsona =**  **1,978776** | **>0,05** |
| **Comorbidities:**  **None**  **Cardiovascular diseases**  **Cardiovascular diseases & DM**  **DM** | **41 (58,57%)**  **22 (31,43%)**  **6 (8,57%)**  **1 (1,43%)** | **27 (54%)**  **18 (36%)**  **5 (10%)**  **0 (0%)** | **Chi2 Pearsona =**  **1,069641** | **>0,05** |

**Table 2. Clinical and pathological characteristics of the study group (supplemental)**

|  |  |
| --- | --- |
| **Characteristics** | **Study group (n = 70)** |
| **Histological type**   * **Serous carcinoma** * **Undifferentiated carcinoma** * **Clear cell carcinoma** * **Seromucinous carcinoma** * **Mucinous carcinoma** * **Endometrioid carcinoma** | **37 (52,86%)**  **5 (7,14%)**  **8 (11,43%)**  **3 (4,29%)**  **7 (10%)**  **10 (14,29%)** |
| **Grading**   * **G1** * **G2** * **G3** | **7 (10%)**  **21 (30%)**  **42 (60%)** |
| **FIGO stage**   * **I** * **II** * **III** * **IV** | **10 (14,29%)**  **0 (0,00%)**  **38 (54,29%)**  **22 (31,43%)** |

**Table 3 Statistical analysis of serum free IGF-1 levels in the OC patients and controls**

|  |  |  |
| --- | --- | --- |
| **IGF–1 [ng/ml]** | **Control group** | **Study group** |
| **No. of patients** | **50** | **70** |
| **Min** | **4,40** | **5,00** |
| **Max** | **18,60** | **21,00** |
| **Median** | **9,90** | **13,40** |
| **Arithmetical mean** | **10,00** | **12,98** |
| **Standard deviation** | **4,38** | **4,61** |
| **Asymmetry coefficient** | **0,52** | **-0,29** |
| **Statistical analysis** | **T Student Test = 2,362432; p<0,05**  **(p= 0,022088)** | |

**Table. 4 Statistical analysis of serum IGF-1 levels in OC women (premenopausal women) and controls (premenopausal)**

|  |  |  |
| --- | --- | --- |
| **IGF–1 [ng/ml]** | **Control group (premenopausal)** | **Study group**  **(premenopausal)** |
| **No. of patients** | **30** | **49** |
| **Min** | **4,40** | **9,60** |
| **Max** | **18,60** | **21,00** |
| **Median** | **11,20** | **15,20** |
| **Arithmetical mean** | **11,16** | **15,21** |
| **Standard deviation** | **4,80** | **3,01** |
| **Asymmetry coefficient** | **0,30** | **-0,60** |
| **Statistical analysis** | **T Student Test = 2,986286; p<0,05**  **(p=0,005476)** | |

**Table. 5 Statistical analysis of serum free IGF-1 concentrations in patients with OC with regard to histological tumor type**

|  |  |  |
| --- | --- | --- |
| **IGF-1[ng/ml]** | **HISTOLOGICAL TUMOR TYPE** | |
| **Serous carcinoma** | **others** |
| **No. of patients** | **37** | **33** |
| **Min** | **5,00** | **5,70** |
| **Max** | **21,00** | **19,00** |
| **Median** | **12,85** | **13,80** |
| **Arithmetical mean** | **12,34** | **13,78** |
| **Standard deviation** | **5,14** | **3,92** |
| **Asymmetry coefficient** | **0,03** | **-0,77** |
| **Statistical analysis** | **T Student Test = 0,826354;p>0,05** | |

**Table. 6 Statistical analysis of serum free IGF-1 levels in patients with OC with regard to tumor grade**

|  |  |  |  |
| --- | --- | --- | --- |
| **IGF-1[ng/ml]** | **TUMOR GRADE** | | |
| **G1** | **G2** | **G3** |
| **No. of patients** | **7** | **21** | **42** |
| **Min** | **5,70** | **5,00** | **5,40** |
| **Max** | **16,60** | **21,00** | **19,50** |
| **Median** | **15,30** | **14,05** | **13,40** |
| **Arithmetical mean** | **12,53** | **13,28** | **12,92** |
| **Standard deviation** | **5,95** | **5,58** | **4,24** |
| **Asymmetry coefficient** | **-1,64** | **-0,13** | **-0,39** |
| **Statistical analysis** | **Kruskal Wallis ANOVA = 0,044297; p>0,05** | | |

**Table. 7 Statistical analysis of serum free IGF-1 concentrations in patients with OC with regard to FIGO stage (2014)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **IGF-1[ng/ml]** | **FIGO STAGE** | | | |
| **I** | **II** | **III** | **IV** |
| **No. of patients** | **10** | **0** | **38** | **22** |
| **Min** | **5,70** | **-** | **5,00** | **5,40** |
| **Max** | **16,60** | **-** | **21,00** | **19,00** |
| **Median** | **9,30** | **-** | **13,50** | **14,25** |
| **Arithmetical mean** | **10,53** | **-** | **13,56** | **13,01** |
| **Standard deviation** | **5,56** | **-** | **4,90** | **4,37** |
| **Asymmetry coefficient** | **0,95** | **-** | **-0,16** | **-0,71** |
| **Statistical analysis** | **Kruskal Wallis ANOVA = 0,622699; p>0,05** | | | |

**Table 8 Statistical analysis of the correlation (Pearson Correlation): between serum free IGF-1 concentration in OC patients and their growth.**

|  |  |  |
| --- | --- | --- |
| **IGF-1** | **GROWTH** | |
| **r(X,Y)** | **p** |
| **0,013369** | **p>0,05** |

**Table 9** **Statistical analysis of the correlation (Spearman’s rank - R): between serum free IGF-1 concentration and Ca125 in patients with OC**

**.**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Ca 125** | |
| **R** | **p** |
| **IGF-1** | **-0,019468** | **p>0,05** |